Foundation Medicine Announces New Data Highlighting FoundationOne™ and FoundationOne™ Heme to be Presented at the AACR Annual Meeting 2014

Business Wire

CAMBRIDGE, Mass.--(BUSINESS WIRE)--

Foundation Medicine, Inc. (FMI) today announced that new clinical data including additional validation for FoundationOne™ and FoundationOne™ Heme will be presented at the American Association of Cancer Research (AACR) Annual Meeting 2014 taking place April 5-9, 2014 at the San Diego Convention Center.

“These data build on the growing body of clinical evidence highlighting the benefit of comprehensive genomic profiling with FoundationOne, specifically in patients with advanced cancers,” said Vincent Miller, M.D., chief medical officer, Foundation Medicine. “Along with our collaborators, we look forward to sharing new data that expand on the analytic validation study we published last year on FoundationOne to include the validation of gene fusions, which are identified by FoundationOne Heme. This additional class of genomic alterations is a common driver of hematologic malignancies, sarcomas and pediatric cancers. We look forward to sharing these new data on FoundationOne and FoundationOne Heme with the oncology community at AACR.”

The schedule for poster presentations by Foundation Medicine and its collaborators is as follows:

Date & Time: Monday, April 7, 2014 from 8 a.m. to 12 p.m. PT
Title: A computational method for somatic versus germline variant status determination from targeted next-generation sequencing of clinical cancer specimens without a matched normal control
Abstract number: 1893
Location: Hall A-E, Poster Section 37
Poster Board Number: 18

Date & Time: Tuesday, April 8, 2014 from 8 a.m. to 12 p.m. PT
Title: Development and validation of a clinical next-generation sequencing-based assay for hematologic malignancies
Abstract number: 3570
Location: Hall A-E, Poster Section 23
Poster Board Number: 11
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Tuesday, April 8, 2014 from 1 p.m. to 5 p.m. PT
Title: Analytical validation of solid tumor fusion gene detection in a comprehensive NGS-based clinical cancer genomic test
Abstract number: 4699
Location: Hall A-E, Poster Section 37
Poster Board Number: 15
Collaborator: Memorial Sloan-Kettering Cancer Center

Date & Time: Tuesday, April 8, 2014 from 1 p.m. to 5 p.m. PT
Title: Prospective next-generation sequencing (NGS) of rare or poor prognosis cancers
Abstract number: 4261
Location: Hall A-E, Poster Section 19
Poster Board Number: 4
Collaborator: Cancer Institute of New Jersey

Date & Time: Tuesday, April 8, 2014 from 1 p.m. to 5 p.m. PT
Title: An unbiased survey of cancer-related rearrangements in 5,917 solid tumors identifies therapeutically actionable fusions across multiple disease subtypes
Abstract number: 4268
Location: Hall A-E, Poster Section 19
Poster Board Number: 11

About Foundation Medicine

Foundation Medicine (FMI) is a molecular information company dedicated to a transformation in cancer care in which treatment is informed by a deep understanding of the genomic changes that contribute to each patient's unique cancer. The company's clinical assays, FoundationOne for solid tumors and FoundationOne Heme for hematologic malignancies, sarcomas and pediatric cancers, each provide a fully informative genomic profile to identify the molecular alterations in a patient's cancer and match them with relevant targeted therapies and clinical trials. Foundation Medicine's molecular information platform aims to improve day-to-day care for patients by serving the needs of clinicians, academic researchers and drug developers to help advance the science of molecular medicine in cancer. For more information, please visit www.FoundationMedicine.com or follow Foundation Medicine on Twitter (@FoundationATCG).

Foundation Medicine® is a registered trademark, and FoundationOneTM is a trademark, of Foundation Medicine, Inc.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the clinical benefits of FoundationOne and FoundationOne Heme. All such forward-looking statements are based on management's current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include that FoundationOne and FoundationOne Heme will not be able to identify genomic alterations in the same manner as prior clinical and analytical validation studies and the risks described under the caption “Risk Factors” in Foundation Medicine’s Annual Report on Form 10-K for the year ended December 31, 2013, which is on file with the Securities and Exchange Commission, as well as other risks detailed in Foundation Medicine’s subsequent filings with the Securities and Exchange Commission. All information in this press release is as of the date of the release, and Foundation Medicine undertakes no duty to update this information unless required by law.

Contact:
Media Contact:
Pure Communications, Inc.
Dan Budwick, 973-271-6085
dan@purecommunicationsinc.com
or
Investor Contact:
Foundation Medicine
Matt Clawson, 617-418-2283
ir@foundationmedicine.com

View Comments (0)